Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Conclusions MYC-amplified neuroblastomas are extremely rare and seem to present with distinct clinicopathological features.
|
29426276 |
2019 |
Neuroblastoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Stage 4 NBL with MYC-N amplification and 1p36 deletion was diagnosed in an 11 months old girl.
|
31441848 |
2019 |
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma.
|
31406244 |
2019 |
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Specific inhibition of hyperactive rRNA synthesis and protein translation was shown to be an effective way to suppress MYC/MYCN protein expression and neuroblastoma growth.
|
29464082 |
2018 |
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These data implicate tissue-specific enhancers in defining often highly tumor-specific 'MYC target gene signatures' and identify disruption of the MYCN enhancer regulatory axis as a promising therapeutic strategy in neuroblastoma.
|
29379199 |
2018 |
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These data suggest that epigenetic and posttranslational inhibition of MYC/MYCN-driven pathways may have significant clinical efficacy against neuroblastoma.
|
30153557 |
2018 |
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
N6,2'-O-dibutyryladenosine 3':5'cyclic monophosphate (Bt2cAMP) inhibited neuroblastoma cell growth by inhibiting c-MYC and HDAC8 expression and activating caspase 3.
|
30237861 |
2018 |
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We found that MELK is a direct transcription target of MYCN and MYC in NB, and MYCN increases MELK expression via direct promoter binding.
|
29416794 |
2018 |
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our study implicates the role of BORIS/CTCFL in maintenance of stemness and in transition from mesenchymal to epithelial state in MYC amplified neuroblastoma IMR-32 cells.
|
28104398 |
2017 |
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Analysis of human neuroblastoma tumor specimens revealed that MYC up-regulation correlates with markers of TAM infiltration.
|
29207662 |
2017 |
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Although MYC translocations define Burkitt lymphoma and MYC protein expression is a poor prognostic factor in undifferentiated neuroblastomas, the distribution of MYC protein (c-MYC) across other pediatric small round blue cell tumors (SRBCT) has not been well characterized.
|
28521631 |
2017 |
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MYC and MYCN control the expression of PD-L1 in neuroblastoma cells both <i>in vitro</i> and <i>in vivo</i> Consistently, abundance of PD-L1 transcript correlates with MYC expression in primary neuroblastoma.<b>Conclusions:</b> The combination of PD-L1 and HLA class I represents a novel prognostic biomarker for neuroblastoma.
|
28270499 |
2017 |
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This hypothesis-driven systems bioinformatics work offered novel insights into the PRC2-mediated tumor cell growth and differentiation in neuroblastoma, which may exert oncogenic effects together with MYC regulation.
|
28984200 |
2017 |
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These data highlight a novel route for cell death induction by PARP inhibitors and support their introduction, together with CHK1 inhibitors, in therapeutic approaches for neuroblastomas with high MYC(N) activity.
|
28394338 |
2017 |
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Isoxazole compound ML327 blocks MYC expression and tumor formation in neuroblastoma.
|
29207623 |
2017 |
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox.
|
28684529 |
2017 |
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Amplification of the MYCN is the predominant marker for aggressive NB and correlates with poor prognosis, while c-MYC overexpression is a defining feature of MB subgroups inflected with aggressive biological behavior and increased likelihood of metastasis.
|
26373717 |
2016 |
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Of note, expressions of MCT1 and MCT2 were each significantly elevated in MYCN-amplified neuroblastomas and C-MYC-overexpressing lymphomas than in tumors without MYC overexpression, correlating with poor prognosis and unfavorable patient survival.
|
26434591 |
2016 |
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Here, we found miR-1303 was upregulated in NB cells and tissues, miR-1303 overexpression promoted the proliferation of SH-SY5Y NB cell investigated by MTT assay, colony formation assay and anchorage-independent growth ability assay, while miR-1303 knockdown reduced this effect. mechanism analysis suggested glycogen synthase kinase 3 beta (GSK3β) and secreted frizzled-related protein 1 (SFRP1) were the target of miR-1303, luciferase assay revealed miR-1303 directly bound to the 3'UTR of GSK3β and SFRP1. miR-1303 increased expression of MYC and CyclinD1, and decreased the expression of p21 and p27, and further demonstrated miR-1303 promotes NB proliferation.
|
27434867 |
2016 |
Neuroblastoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Amplification of the MYCN oncogene, a member of the MYC family of transcriptional regulators, is one of the most powerful prognostic markers identified for poor outcome in neuroblastoma, the most common extracranial solid cancer in childhood.
|
27448979 |
2016 |
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MYC coordinately regulates polyamine homeostasis as these essential cations support MYC functions, and drugs that antagonize polyamine sufficiency have synthetic-lethal interactions with MYC Neuroblastoma is a lethal tumor in which the MYC homologue MYCN, and ODC1, the rate-limiting enzyme in polyamine synthesis, are frequently deregulated so we tested optimized polyamine depletion regimens for activity against neuroblastoma.
|
27012811 |
2016 |
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance.
|
27197232 |
2016 |
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Immunostaining for MYCN and MYC protein was performed on 357 undifferentiated/poorly differentiated neuroblastomas.
|
26035700 |
2015 |
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Clinical data set analysis of MYCN, MYC and TWIST1 expression permits us to confirm that TWIST1 expression is upregulated in MYCN amplified neuroblastoma but also in a subset of neuroblastoma harboring high expression of MYCN or MYC without gene amplification.
|
25475555 |
2015 |
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In sharp contrast to MYCN, enforced expression of c-MYC did not enhance OCT4 expression in human neuroblastoma cells.
|
25880909 |
2015 |